HEMAB THERAPEUTICS - TRIAL DESIGN INCLUDES 24-WEEK RUN-IN, 48-WEEK TREATMENT; PRIMARY ENDPOINT IS ANNUALIZED TREATED BLEED RATE

Reuters · 2d ago

Please log in to view news